 |
 |

Maintenance of Adrenal Cortical Responsiveness During Prolonged Corticoid TherapyEvaluation of Intermittent Administration of Repository Corticotropin Injection
IRVING I. YOUNG, M.D.;
VITO De FILIPPIS;
FRANK L. MEYER, M.D.;
WILLIAM Q. WOLFSON, M.D.
AMA Arch Intern Med. 1957;100(1):1-10.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
When given in adequate amounts, the therapeutically and metabolically active adrenal 17-hydroxycorticoids (17-OHCS) suppress the activity of the normal pituitaryadrenal axis. This is accomplished not by a direct action upon the adrenal cortex but by suppressing endogenous secretion of pituitary corticotropin (ACTH). This effect occurs to only a slight degree with a pure mineralocorticoid, such as desoxycorticosterone, but is marked with all of the adrenal corticoids used for systemic treatment, such as cortisone, hydrocortisone, prednisone, and prednisolone.
The first consequent of suppression of endogenous corticotropin secretion by exogenous corticoid is a marked diminution in the secretion of hydrocortisone, corticosterone, and adrenal androgens by the adrenal cortex; apparently diminution in aldosterone secretion is less pronounced. If adequate doses of exogenous steroid are given for long periods, the adrenal cortex slowly involutes and becomes atrophic. Accompanying this anatomic decrease in mass is a physiologic loss of sensitivity to stimulation, characterized by a
. . . [Full Text PDF of this Article]
Author Affiliations
Detroit
From the Department of Medicine, Wayne State University College of Medicine, and City of Detroit Receiving Hospital. Present address (Dr. Wolfson) 130 Waverly, Highland Park, Mich.
Footnotes
Submitted for publication Nov. 29, 1956.
This study was supported in part by grants from the Michigan Chapter, Arthritis and Rheumatism Foundation, and The Armour Laboratories.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|